Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
87%
Atrial Fibrillation
60%
Human Immunodeficiency Virus
41%
Blood Donor
40%
Quality Adjusted Life Year
36%
Blood Transfusion
35%
Hepatitis B Virus
28%
Apoplexy
20%
Health Care
16%
Antiretroviral Therapy
15%
Rivaroxaban
15%
Hepatitis B
15%
Dabigatran
15%
Trastuzumab Deruxtecan
15%
Blood Safety
14%
Anticoagulation
13%
Infection
12%
Hepatitis Virus
12%
Hepatitis C Virus
12%
Nucleic Acid
12%
Erythrocyte Transfusion
12%
Quality of Life
11%
Bleeding
11%
Metastatic Breast Cancer
11%
Decision Making
10%
HIV/AIDS
9%
Drug Therapy
9%
Vaccination Coverage
9%
Outpatient
8%
Cardiology
8%
Screening
8%
Lifespan
8%
Acenocoumarol
7%
Obstetric Procedure
7%
Thrombocyte Transfusion
7%
Anticoagulant
7%
Hepatitis C
7%
Nadroparin Calcium
7%
Rotavirus Vaccine
7%
Leukocyte
7%
Total Knee Arthroplasty
7%
Q Fever
7%
New-Onset Atrial Fibrillation
7%
Electrocardiogram
7%
4 Iodo 2,5 Dimethoxyamphetamine
7%
Human Immunodeficiency Virus Prevalence
7%
Measles Vaccine
7%
Apixaban
7%
Patient Referral
7%
Nursing and Health Professions
Cost Effectiveness Analysis
61%
Human Immunodeficiency Virus
48%
Atrial Fibrillation
44%
Health Economics
34%
Blood Transfusion
33%
Tertiary Care Center
31%
Economic Evaluation
26%
Blood Donor
24%
Hepatitis C
22%
Hepatitis B
19%
Antibody Screening
17%
Antiretroviral Therapy
15%
Infection
15%
Nucleic Acid
14%
Anticoagulation
14%
Cost Control
13%
Health Service
13%
Quality Adjusted Life Year
13%
Nucleic Acid Amplification
13%
Erythrocyte Transfusion
12%
Vaccination Policy
11%
Human Immunodeficiency Virus Antibody
10%
Cost Utility Analysis
9%
Cost Benefit Analysis
8%
Virus Hepatitis
8%
Screening
8%
Incremental Cost-Effectiveness Ratio
8%
Quality of Life
7%
Dabigatran
7%
Thrombocyte Transfusion
7%
Erythrocyte Concentrate
7%
Outpatient
7%
Blood Component Therapy
7%
Vaccination Coverage
7%
Primary Medical Care
7%
Intensive Care Unit
7%
New-Onset Atrial Fibrillation
7%
Obstetric Procedure
7%
Electrocardiogram
7%
Acenocoumarol
7%
Vaccine Efficacy
7%
Systematic Review
7%
Measles
7%
Trastuzumab Deruxtecan
7%
Patient History of Chemotherapy
7%
Pandemic
7%
Severe Acute Respiratory Syndrome
7%
Seroprevalence
7%
Cross-Sectional Study
7%
Serology
7%
Keyphrases
Cost-effectiveness
42%
Atrial Fibrillation
41%
Netherlands
36%
Dabigatran
29%
Rivaroxaban
26%
Nadroparin
23%
Zimbabwe
23%
Anticoagulants
16%
Apixaban
15%
Arthroplasty Surgery
15%
Tertiary Hospital
15%
Hepatitis C Virus Screening
15%
Vitamin K Antagonists
13%
Screening Strategy
12%
Cost Savings
12%
Bleeding
10%
Cost-effectiveness Analysis
9%
Budget Impact
9%
Hepatitis C Virus
9%
Non-vitamin K Antagonist Oral Anticoagulants
8%
Dalteparin
8%
Health Economic Evaluation
7%
Adult Outpatients
7%
Screening Program
7%
Anti-Xa Activity
7%
Nonselective β-blockers
7%
Pathogen Inactivation
7%
Anticoagulation Management
7%
Platelet Transfusion
7%
High Dose
7%
Blood Component Transfusion
7%
Cost Claims
7%
Smokers
7%
Risk Factors for Stroke
7%
Ex-smokers
7%
Risk Management Model
7%
Pharmacokinetics
7%
Transfusion Risks
7%
Adherence to Protocols
7%
Intensive Care Unit
7%
Randomized pilot Trial
7%
Reversal Agents
7%
Harare
7%
Accra-Ghana
7%
Oaxaca-Blinder Decomposition
7%
Age Groups
7%
Unit Production Cost
7%
Transfusion-related Adverse Events
7%
In Care
7%
Migrants
7%